Amyotrophic Lateral Sclerosis - Pipeline, Assessment and Analysis During H1 2017 To 2022

Amyotrophic Lateral Sclerosis   

Overview

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1306952-amyotrophic-lateral-sclerosis-pipeline-review-h1-2017

Amyotrophic Lateral Sclerosis Industry Major Outlook

The Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 2, 24, 11, 1, 72, 21 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 42 and 7 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Amyotrophic Lateral Sclerosis - Competitive Analysis

Key players are making innovative developments in Amyotrophic Lateral Sclerosis industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System). 
- The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects. 

Table of Contents 
Table of Contents 2 
Introduction 6 
Amyotrophic Lateral Sclerosis - Overview 7 
Amyotrophic Lateral Sclerosis - Therapeutics Development 8 
Amyotrophic Lateral Sclerosis - Therapeutics Assessment 31 
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 47 
Amyotrophic Lateral Sclerosis - Drug Profiles 87 
Amyotrophic Lateral Sclerosis - Dormant Projects 417 
Amyotrophic Lateral Sclerosis - Discontinued Products 424 
Amyotrophic Lateral Sclerosis - Product Development Milestones 425 
Appendix 436

List of Tables 
Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2017 
Number of Products under Development by Companies, H1 2017 
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1306952-amyotrophic-lateral-sclerosis-pipeline-review-h1-2017

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.